VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31

VITASPRING BIOMEDICAL CO. LTD.

Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 17, 2026

$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $6.58M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jul 31, 2026

Vitaspring Biomedical reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Vitaspring Biomedical's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Vitaspring Biomedical's annual and quarterly filings with the SEC
Per-share figures adjusted for the 5-for-1 split on Jun 29, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VSBC.

Company	Revenue	Growth
CRL	$4.00B	-0.7%
MXCT	$31.05M	-13.2%
FOXO	$17.86M	+44.0%
ONMD	$1.46M	+216.5%
VSBC	$0	–
IBAC	–	–

Company

Exchange: OTC
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: January 31
Auditor: JP CENTURION & PARTNERS PLT
SEC CIK: 1697884

Advertisement
300 × 250